Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 17, Issue 14, 2003, Pages 1665-1670

  Dams, Riet ^a,b   Murphy, Constance M ^a   Lambert, Willy E ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATMOSPHERIC IONIZATION; ATMOSPHERIC PRESSURE; BODY FLUIDS; CLINICAL RESEARCH; DIRECT INJECTION; DRUG PRODUCTS; IONIZATION OF LIQUIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; REGRESSION ANALYSIS; STABILITY CRITERIA;

ANALYSIS TIME; ANALYTES; DRUG TESTING; GRADIENT ELUTION; LC-MS-MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; OPIOIDS; REVERSED PHASE CHROMATOGRAPHY; SAMPLE PREPARATION;

METABOLITES;

2 ETHYL 1,5 DIMETHYL 3,3 DIPHENYLPYRROLINIUM; 3 HYDROXYBENZOYLECGONINE; 3 HYDROXYCOCAINE; 4 HYDROXYBENZOYLECGONINE; 4 HYDROXYCOCAINE; ACETYLCODEINE; ANHYDROECGONINE METHYL ESTER; BENZOYLECGONINE; BENZOYLNORECGONINE; COCAINE; COCAINE DERIVATIVE; CODEINE; DEUTERIUM; DIAMORPHINE; DIMEPHEPTANOL; DRUG METABOLITE; ECGONINE; ECGONINE ETHYL ESTER; ECGONINE METHYL ESTER; HOMOCOCAINE; ILLICIT DRUG; METHADONE; MORPHINE; MORPHINE 6 ACETATE; NORCOCAETHYLENE; NORCOCAINE; NORCODEINE; NORMORPHINE; OPIATE; PAPAVERINE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; ATMOSPHERIC PRESSURE; CALIBRATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DILUTION; DRUG ABUSE; DRUG DETERMINATION; DRUG MONITORING; DRUG URINE LEVEL; ELUTION; HEALTH CARE ORGANIZATION; HUMAN; IONIZATION; LINEAR REGRESSION ANALYSIS; NORMAL HUMAN; PATIENT COMPLIANCE; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; STANDARD; TANDEM MASS SPECTROMETRY; TIME; URINALYSIS; URINE; VALIDATION PROCESS;

EID: 0037932381     PISSN: 09514198     EISSN: None     Source Type: Journal    
DOI: 10.1002/rcm.1098     Document Type: Article

References (40)

1. Cone EJ. Forensic Sci. Int. 2001; 121: 7.
2. Wolff K, Farrell M, Marsden J, Monteiro MG, Ali R, Welch S, Strang J. Addiction 1999; 94: 1279.
3. Maurer HH, Kraemer T, Ledvinka O, Schmitt CJ, Weber AA. J. Chromatogr. B 1997; 689: 81.
4. Maurer HH. Combinat. Chem. High Throughput Screening 2000; 3: 467.
5. Cone EJ, Preston KL. Therapeut Drug Monit. 2002; 24: 193.
6. Huestis MA, Cone EJ, Wong CJ, Umbricht A, Preston KL. J. Anal. Toxicol. 2000; 24: 509.
7. Preston KL, Huestis MA, Wong CJ, Umbricht A, Goldberger BA, Cone EJ. J. Anal. Toxicol. 1999; 23: 313.
8. Rivier L. Best Practice Res. Clin. Endocrinol. Metab. 2000; 14: 147.
9. Vandevenne M, Vandenbussche H, Verstraete A. Acta Clin. Belg. 2000; 55: 323.
10. Riley KJ, Lu NT, Meeker JE, Lo P, Fortner N, Taylor BG. Addiction Biol. 2001; 6: 83.
11. Breindahl T, Andreasen K. J. Chromatogr. B 1999; 732: 155.
12. Hoja H, Marquet P, Verneuil B, Lotfi H, Penicaut B, Lachatre G. J. Anal. Toxicol. 1997; 21: 116.
13. Dams R, Benijts T, Lambert WE, De Leenheer AP. J. Chromatogr. B 2002; 773: 53.
14. Maurer HH. J. Chromatogr. B 1998; 713: 3.
15. Marquet P, Lachatre G. J. Chromatogr. B 1999; 733: 93.
16. Marquet P. Therapeut. Drug Monit. 2002; 24: 255.
17. Van Bocxlaer JF, Clauwaert KM, Lambert WE, Deforce DL, Van den Eeckhout EG, De Leenheer AP. Mass Spectrom. Rev. 2000; 19: 165.
18. Henion J, Brewer E, Rule G. Anal. Chem. 1998; 70: 650A.
19. Bogusz MJ. J. Chromatogr. B 2000; 748: 3.
20. Nishikawa M, Nakajima K, Tatsuno M, Kasuya F, Igarashi K, Fukui M, Tsuchihashi H. Forensic Sci. Int. 1994; 66: 149.
21. Bogusz MJ, Maier RD, Erkens M, Driessen S. J. Chromatogr. B 1997; 703: 115.
22. Bogusz MJ, Maier RD, Kruger KD, Kohls U. J. Anal. Toxicol. 1998; 22: 549.
23. Bogusz MJ, Maier RD, Erkens M, Kohls U. J. Anal. Toxicol. 2001; 25: 431.
24. Weinmann W, Svoboda M. J. Anal. Toxicol. 1998; 22: 319.
25. Fitzgerald RL, Rivera JD, Herold DA. Clin. Chem. 1999; 45: 1224.
26. Cailleux A, Le Bouil A, Auger B, Bonsergent G, Turcant A, Allain P. J. Anal. Toxicol. 1999; 23: 620.
27. Schanzle G, Li SX, Mikus G, Hofmann U. J. Chromatogr. B 1999; 721: 55.
28. Katagi M, Nishikawa M, Tatsuno M, Miyazawa T, Tsuchihashi H, Suzuki A, Shirota O. Jpn J. Toxicol. Environ. Health 1998; 44: 107.
29. Katagi M, Tatsuno M, Miki A, Nishikawa M, Tsuchihashi H. J. Anal. Toxicol. 2000; 24: 354.
30. Katagi M, Nishikawa M, Tatsuno M, Miki A, Tsuchihashi H. J. Chromatogr. B 2001; 751: 177.
31. Needham SR, Jeanville PM, Brown PR, Estape ES. J. Chromatogr. B 2000; 748: 77.
32. Jeanville PM, Estape ES, Needham SR, Cole MJ. J. Am. Soc. Mass Spectrom. 2000; 11: 257.
33. Jeanville PM, Estape ES, Torres-Negron I, Marti A. J. Anal. Toxicol. 2001; 25: 69.
34. Dams R, Murphy CM, Choo RE, Lambert WE, De Leenheer AP, Huestis MA. Anal. Chem. 2003; 75: 798.
35. European Union (EU). European Laboratory Guidelines for Legally Defensible Workplace Drug Testing 1. Urine Drug Testing.
36. Substance Abuse and Mental Health Services Administration (SAMSHA). Mandatory Guidelines for Federal Workplace Drug Testing Programs, 2001; 1-56.
37. Dams R, Lambert WE, Clauwaert KM, De Leenheer A. J. Chromatogr. A 2000; 896: 311.
38. Poochikian GK, Cradock JC. J. Pharm. Sci. 1980; 69: 637.
39. Drummer OH, Gerostamoulos J. Therapeut. Drug Monit. 2002; 24: 199.
40. Johansson M, Eksborg S, Arbin A.J. Chromatogr. 1983;275:355.